Zelluna Activates First Clinical Site for ZIMA-101 Trial, Advances TCR-NK Therapy
Event summary
- Zelluna activated its first clinical site, The Christie NHS Foundation Trust, for the ZIMA-101 Phase 1 trial on May 6, 2026.
- The company received CTA approval from the MHRA and REC on February 20, 2026, for its lead candidate ZI-MA4-1.
- Zelluna reported Q1 2026 operating expenses of MNOK 20.4 and a cash position of MNOK 49.3 as of March 31, 2026.
- The company expects initial clinical data from mid-2026 and has a financial runway into Q1 2027.
The big picture
Zelluna's transition from regulatory submission to clinical execution marks a pivotal phase in the development of its TCR-NK therapy platform. The activation of the first clinical site for the ZIMA-101 trial positions the company to generate critical clinical data, which will be key in validating its approach to treating solid cancers. The strategic collaboration with Etcembly Ltd and the partnership with Medpace further bolster Zelluna's capabilities in AI-enabled TCR engineering and clinical trial support, respectively.
What we're watching
- Clinical Execution
- The pace at which Zelluna doses the first patients in the ZIMA-101 study will determine the timeline for initial clinical data.
- Pipeline Advancement
- Whether Zelluna can sustain its pipeline progress while executing the Phase 1 trial will be critical for long-term potential.
- Financial Management
- How Zelluna manages its cash position and operating expenses will impact its runway into Q1 2027.
Related topics